AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for Hospitalized COVID-19 Patients
AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for CKD Patients With and Without Type-2 Diabetes
Shots:
- The CALAVI program involves assessing of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19, but not on assisted ventilation. The studies are being conducted in the US and outside the US including the EU, Japan and South America
- The drug demonstrated the clinical improvement in peer-reviewed case series of 19 hospitalized patients with COVID-19 and hypoxia and/or inflammation. Results were published in Science Immunology
- Calquence is a BTK inhibitor, act by inhibiting its activity and has received the US FDA approval for hematological malignancies
Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter
Related news: AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19